Therapeutic innovations in inflammatory bowel diseases.
Inflammatory bowel disease (IBD) is a spectrum of complex multifactorial immune disorders characterized by chronic inflammation of the gut. Significant advances have been made in unraveling the pathogenesis of this disease spectrum, which have spurred the discovery of new therapeutic targets and strategies. In this review, we highlight the emerging new classes of IBD therapeutics under clinical evaluation and their method of action, including JAK inhibitors, anti-SMAD7 oligonucleotides, and cell-based therapies. Moreover, we discuss how an approach based on unique molecular insights in a given patient will, in the future, lead to a truly individualized/tailored disease management, starting at diagnosis, aiding in prognosis, and resulting in a personalized therapeutic approach.
Department of Clinical and Experimental Medicine, University Hospitals Leuven, Leuven, Belgium.
W
W
Vanhove
Department of Clinical and Experimental Medicine, University Hospitals Leuven, Leuven, Belgium.
K
K
Nys
Department of Clinical and Experimental Medicine, University Hospitals Leuven, Leuven, Belgium.
S
S
Vermeire
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D016207:Cytokines / Q000037:antagonists & inhibitors*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000628:therapy*; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D007962:Leukocytes / Q000187:drug effects; D008954:Models, Biological; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D057285:Precision Medicine
D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D016376:Oligonucleotides, Antisense; D053612:Janus Kinases